Back to News
Market Impact: 0.15
Daré Bioscience Highlights 187-Fold Lower Sildenafil Exposure In Phase 1 Study
Source: Nasdaq
Healthcare & Biotech
Daré Bioscience said clinical data from a Phase 1 study of its investigational Sildenafil Cream, 3.6%, will be presented at the SMSNA Annual Fall Scientific Meeting in Orlando, Florida. The article provides no study results or additional clinical details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
DARE0.30
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- William Blair downgrades Alignment Healthcare stock rating on cost pressures